Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0DLZVY)
ADC Name
SC-007
Synonyms
SC-007
   Click to Show/Hide
Organization
Stemcentrx (Top20 MNC) (Originator)
Drug Status
Phase 1 (discontinued)
Antibody Name
Undisclosed
Antigen Name
Undisclosed
Payload Name
PBD dimer
  Payload Info 
Payload Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Undisclosed
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Gastric cancer
1 Trials
Clinical trial identifier
NCT03253185
Colorectal cancer
1 Trials
Clinical trial identifier
NCT03253185
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03253185
PHASE1
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Undisclosed  NCT03253185
Phase 1
An open label study of SC-007 in subjects with advanced cancer.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Eligible patients have advanced CRC (≥2 prior metastatic regimens, including pembrolizumab for MSI-H) or gastric cancer (≥2 prior lines, including HER2-targeted therapy if applicable), with ECOG 0-1 and adequate organ function. Exclusions include significant comorbidities, uninterpretable QTc, and prior exposure to PBD/indolinobenzodiazepine drugs.

   Click to Show/Hide
Administration Dosage
.
Related Clinical Trial
NCT Number NCT03253185  Clinical Status PHASE1
Clinical Description An Open Label Study of SC-007 in Subjects With Advanced Cancer
Primary Endpoint
The primary safety endpoint is the incidence of dose-limiting toxicities (DLTs) during the first treatment cycle (up to 21 days), graded per NCI CTCAE v4.03 criteria.
Other Endpoint
Key efficacy measures include clinical benefit rate (CBR=CR+PR+SD), progression-free survival (PFS), and overall survival (OS) over 4 years. Pharmacokinetic parameters (Cmax, Tmax, AUC, T1/2, Ctrough) and QTcF changes are monitored for 1 year, while anti-drug antibodies (ATAs) and objective response metrics (ORR, DOR) are tracked for 4 years.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Patients with advanced cancer (Colorectal Cancer or Gastric Cancer).
Administration Dosage
SC-007 iv.
Related Clinical Trial
NCT Number NCT03253185  Clinical Status Phase 1
Clinical Description An open label study of SC-007 in subjects with advanced cancer.
References
Ref 1 A Study of SC-007 in Subjects With Advanced Cancer
Ref 2 An Open Label Study of SC-007 in Subjects With Advanced Cancer